Search
Samsung Biologics Snaps Up GlaxoSmithKline’s U.S. Facility for $280 Million
1 day ago /
Read about 0 minute
Author：小编
On Wednesday, Samsung Biologics, a key subsidiary of the Samsung Group, revealed that it has secured the Rockville, Maryland-based plant of British pharmaceutical powerhouse GlaxoSmithKline in the United States, at a cost of $280 million. This facility boasts a production capacity of 60,000 liters for active pharmaceutical ingredients. Following the acquisition, Samsung Biologics' overall production capacity will soar to 845,000 liters. The company is set to pour additional resources into expanding its production capabilities and upgrading technological infrastructure, with the aim of bolstering its global supply chain network.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
